Alnylam Pharmaceuticals Inc

자세한 내용은 Alnylam Pharmaceuticals Inc 회사

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Alnylam Pharmaceuticals Inc 정보



종목 코드 ALNY

회사 이름Alnylam Pharmaceuticals Inc

상장일May 28, 2004

CEODr. Yvonne L. Greenstreet, M.D.

직원 수2230

유형Ordinary Share

회계 연도 종료May 28

주소675 W Kendall St

도시CAMBRIDGE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02142-1168

전화16175518200

웹사이트https://www.alnylam.com/

종목 코드 ALNY

상장일May 28, 2004

CEODr. Yvonne L. Greenstreet, M.D.

Alnylam Pharmaceuticals Inc의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

--

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

--

Mr. Peter N. Kellogg

Independent Director

775.00

--

Ms. Colleen F. Reitan

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

수익 분석

통화: USD마지막 업데이트: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

사업별USD

이름

수익

비율

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

기타

50.81M

6.57%

지역별USD

이름

수익

비율

United States

454.57M

58.75%

Europe

157.01M

20.29%

Net revenues from collaborations

61.50M

7.95%

Rest of World

60.63M

7.84%

Royalty revenue

39.98M

5.17%

사업별

지역별

사업별USD

이름

수익

비율

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

기타

50.81M

6.57%

주식 보유 통계

마지막 업데이트: Sat, Aug 16

주주

주주 유형

주주

비율

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

기타

55.28%

주주

비율

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

기타

55.28%

주주 유형

주주

비율

Investment Advisor

68.97%

Investment Advisor/Hedge Fund

21.97%

Hedge Fund

3.70%

Research Firm

1.84%

Sovereign Wealth Fund

1.63%

Bank and Trust

1.27%

Pension Fund

1.27%

Corporation

1.05%

Individual Investor

0.42%

기관 주식 보유



마지막 업데이트: Wed, Oct 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q3

1364

130.85M

99.04%

-1.89M

2025Q2

1300

131.78M

100.54%

-3.28M

2025Q1

1315

132.55M

101.67%

-2.42M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

주주 활동



이름

보유 주식

비율

변동

Chg %

날짜

Capital World Investors

16.81M

12.82%

+55.38K

+0.33%

Jun 30, 2025

Fidelity Management & Research Company LLC

15.05M

11.48%

+427.38K

+2.92%

Jun 30, 2025

The Vanguard Group, Inc.

13.24M

10.1%

+238.24K

+1.83%

Jun 30, 2025

Capital Research Global Investors

7.19M

5.49%

+36.93K

+0.52%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.53M

4.98%

-199.00K

-2.96%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

4.28M

3.27%

-136.87K

-3.10%

Jun 30, 2025

JP Morgan Asset Management

1.79M

1.37%

-87.08K

-4.64%

Jun 30, 2025

Dodge & Cox

3.20M

2.44%

-154.67K

-4.61%

Jun 30, 2025

State Street Investment Management (US)

3.17M

2.42%

-193.48K

-5.75%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.05M

2.32%

-359.26K

-10.55%

Jun 30, 2025

주식 배당금



지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

데이터 없음

주식 분할



날짜

유형

비율

데이터 없음

날짜

유형

비율

데이터 없음

자세한 내용은 Alnylam Pharmaceuticals Inc 회사

Alnylam Pharmaceuticals Inc 정보

Alnylam Pharmaceuticals Inc의 회사 임원진

수익 분석

주식 보유 통계

기관 주식 보유

주주 활동

관련 ETF

주식 배당금

주식 분할